Barac Aleksandra, Kosmidis Chris, Alastruey-Izquierdo Ana, Salzer Helmut J F
Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia.
Med Mycol. 2019 Apr 1;57(Supplement_2):S104-S109. doi: 10.1093/mmy/myy070.
Chronic pulmonary aspergillosis (CPA) is an uncommon, slowly destructive pulmonary disease characterized by progressive cavitation, fibrosis, and pleural thickening. CPA is usually seen in immunocompetent individuals with underlying respiratory disorders. Estimates suggest that up to 3 million people are affected worldwide causing high rates of morbidity and mortality. Pulmonary tuberculosis (TB) seems to be the most relevant driver for the global burden of CPA with estimates suggesting about 1.2 million patients with CPA as a sequel to TB. Diagnosis of CPA is often challenging and delayed and should be based upon a combination of characteristics. The first guidelines for the diagnosis and management of CPA were published in 2016 jointly by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the European Respiratory Society (ERS), and the European Confederation of Medical Mycology (ECMM). CPA continues to receive significant public attention, which resulted in almost 150 newly published papers during 2017. The aim of this mini-review is to highlight the most important published papers from January 2017 to April 2018 to provide an update on current developments in the field of CPA.
慢性肺曲霉病（CPA）是一种罕见的、具有缓慢破坏性的肺部疾病，其特征为进行性空洞形成、纤维化和胸膜增厚。CPA通常见于有基础呼吸系统疾病的免疫功能正常个体。据估计，全球有多达300万人受其影响，导致高发病率和死亡率。肺结核（TB）似乎是导致全球CPA负担的最主要因素，据估计约有120万例CPA患者继发于TB。CPA的诊断往往具有挑战性且会延迟，应基于多种特征进行综合判断。CPA诊断和管理的首个指南于2016年由欧洲临床微生物学和传染病学会（ESCMID）、欧洲呼吸学会（ERS）以及欧洲医学真菌学联合会（ECMM）联合发布。CPA持续受到公众的高度关注，这导致在2017年期间有近150篇新发表的论文。本综述的目的是重点介绍2017年1月至2018年4月期间发表的最重要的论文，以提供CPA领域当前进展的最新情况。
